依伐卡托降低囊性纤维化患者胰腺炎复发风险：病例系列
Reduction of Recurrence Risk of Pancreatitis in Cystic Fibrosis With Ivacaftor: Case Series.
作者信息
Carrion Andres, Borowitz Drucy S, Freedman Steven D, Siracusa Christopher M, Goralski Jennifer L, Hadjiliadis Denis, Srinivasan Saumini, Stokes Dennis C
机构信息
Le Bonheur Children's Hospital, University of Tennessee Health Science Center, Memphis TN.
Women and Children's Hospital at Buffalo, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo NY.
出版信息
J Pediatr Gastroenterol Nutr. 2018 Mar;66(3):451-454. doi: 10.1097/MPG.0000000000001788.
The effect of ivacaftor in patients with cystic fibrosis (CF) with recurrent pancreatitis is unknown. We conducted a multicenter retrospective study of patients with CF taking ivacaftor who had a history of recurrent pancreatitis. During the first 3 months of therapy, only 1 of the 6 patients had an episode of pancreatitis, which was managed on an outpatient basis. Between 3 and 12 months on ivacaftor therapy, none of the patients had recurrence of pancreatitis or required hospitalization. The use of ivacaftor was associated with a reduced frequency and recurrence rate of pancreatitis in patients with CF.
依伐卡托对患有复发性胰腺炎的囊性纤维化（CF）患者的影响尚不清楚。我们对有复发性胰腺炎病史且正在服用依伐卡托的CF患者进行了一项多中心回顾性研究。在治疗的前3个月，6例患者中只有1例发生胰腺炎发作，该患者在门诊接受治疗。在依伐卡托治疗3至12个月期间，没有患者出现胰腺炎复发或需要住院治疗。依伐卡托的使用与CF患者胰腺炎的发作频率和复发率降低有关。
Zotero 插件